Acute promyelocytic leukemia: Clinical and morphologic features and prognostic factors

Giuseppe Awisati, Francesco Lo Coco, Franco Mandelli

Research output: Contribution to journalArticle

Abstract

The most impressive clinical feature of acute promyelocytic leukemia (APL) at diagnosis is the presence in 80% to 90% of patients of a severe hemorrhagic syndrome. Recent data favor a fibrinolytic/proteolytic process rather than a disseminated intravascular coagulation as the mechanism mainly responsible for the hemorrhagic diathesis in APL. Morphologically, two main cytologic variants have been identified: the classical hypergranular APL (M3), which represents the great majority of all APL, and the microgranular variant (M3v), which accounts for about 15% to 20% of all APL. A rare basophilic variant has also been described. With regard to prognosis, it has markedly changed from that of a rapidly fatal acute leukemia to that of a highly curable disease. This revolutionary progress was mainly due to the introduction during the 1990s of all-trans retinoic acid (ATRA) for the treatment of this disease. After the introduction of ATRA, in addition to clinical features such as hyperleukocytosis (white blood cell count > 10 × 109/L) or thrombocytopenia (platelet count <10 × 103/L) at presentation, immunophenotype markers and polymerase chain reaction status for promyelocytic leukemia/retinoic acid receptor-α during follow-up also had an impact on prognosis.

Original languageEnglish
Pages (from-to)4-12
Number of pages9
JournalSeminars in Hematology
Volume38
Issue number1
Publication statusPublished - 2001

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Leukemia
Hemorrhagic Disorders
Retinoic Acid Receptors
Disseminated Intravascular Coagulation
Platelet Count
Leukocyte Count
Thrombocytopenia
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Hematology

Cite this

Acute promyelocytic leukemia : Clinical and morphologic features and prognostic factors. / Awisati, Giuseppe; Lo Coco, Francesco; Mandelli, Franco.

In: Seminars in Hematology, Vol. 38, No. 1, 2001, p. 4-12.

Research output: Contribution to journalArticle

@article{8ad645e3f0dd426cbe719d9bae1ac5d4,
title = "Acute promyelocytic leukemia: Clinical and morphologic features and prognostic factors",
abstract = "The most impressive clinical feature of acute promyelocytic leukemia (APL) at diagnosis is the presence in 80{\%} to 90{\%} of patients of a severe hemorrhagic syndrome. Recent data favor a fibrinolytic/proteolytic process rather than a disseminated intravascular coagulation as the mechanism mainly responsible for the hemorrhagic diathesis in APL. Morphologically, two main cytologic variants have been identified: the classical hypergranular APL (M3), which represents the great majority of all APL, and the microgranular variant (M3v), which accounts for about 15{\%} to 20{\%} of all APL. A rare basophilic variant has also been described. With regard to prognosis, it has markedly changed from that of a rapidly fatal acute leukemia to that of a highly curable disease. This revolutionary progress was mainly due to the introduction during the 1990s of all-trans retinoic acid (ATRA) for the treatment of this disease. After the introduction of ATRA, in addition to clinical features such as hyperleukocytosis (white blood cell count > 10 × 109/L) or thrombocytopenia (platelet count <10 × 103/L) at presentation, immunophenotype markers and polymerase chain reaction status for promyelocytic leukemia/retinoic acid receptor-α during follow-up also had an impact on prognosis.",
author = "Giuseppe Awisati and {Lo Coco}, Francesco and Franco Mandelli",
year = "2001",
language = "English",
volume = "38",
pages = "4--12",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Acute promyelocytic leukemia

T2 - Clinical and morphologic features and prognostic factors

AU - Awisati, Giuseppe

AU - Lo Coco, Francesco

AU - Mandelli, Franco

PY - 2001

Y1 - 2001

N2 - The most impressive clinical feature of acute promyelocytic leukemia (APL) at diagnosis is the presence in 80% to 90% of patients of a severe hemorrhagic syndrome. Recent data favor a fibrinolytic/proteolytic process rather than a disseminated intravascular coagulation as the mechanism mainly responsible for the hemorrhagic diathesis in APL. Morphologically, two main cytologic variants have been identified: the classical hypergranular APL (M3), which represents the great majority of all APL, and the microgranular variant (M3v), which accounts for about 15% to 20% of all APL. A rare basophilic variant has also been described. With regard to prognosis, it has markedly changed from that of a rapidly fatal acute leukemia to that of a highly curable disease. This revolutionary progress was mainly due to the introduction during the 1990s of all-trans retinoic acid (ATRA) for the treatment of this disease. After the introduction of ATRA, in addition to clinical features such as hyperleukocytosis (white blood cell count > 10 × 109/L) or thrombocytopenia (platelet count <10 × 103/L) at presentation, immunophenotype markers and polymerase chain reaction status for promyelocytic leukemia/retinoic acid receptor-α during follow-up also had an impact on prognosis.

AB - The most impressive clinical feature of acute promyelocytic leukemia (APL) at diagnosis is the presence in 80% to 90% of patients of a severe hemorrhagic syndrome. Recent data favor a fibrinolytic/proteolytic process rather than a disseminated intravascular coagulation as the mechanism mainly responsible for the hemorrhagic diathesis in APL. Morphologically, two main cytologic variants have been identified: the classical hypergranular APL (M3), which represents the great majority of all APL, and the microgranular variant (M3v), which accounts for about 15% to 20% of all APL. A rare basophilic variant has also been described. With regard to prognosis, it has markedly changed from that of a rapidly fatal acute leukemia to that of a highly curable disease. This revolutionary progress was mainly due to the introduction during the 1990s of all-trans retinoic acid (ATRA) for the treatment of this disease. After the introduction of ATRA, in addition to clinical features such as hyperleukocytosis (white blood cell count > 10 × 109/L) or thrombocytopenia (platelet count <10 × 103/L) at presentation, immunophenotype markers and polymerase chain reaction status for promyelocytic leukemia/retinoic acid receptor-α during follow-up also had an impact on prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0035145671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035145671&partnerID=8YFLogxK

M3 - Article

C2 - 11172535

AN - SCOPUS:0035145671

VL - 38

SP - 4

EP - 12

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 1

ER -